AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02220270 — intervention group
Intervention type: DEVICE
Intervention: ASD and PDA closure
Study NCT03905785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Samarthan
Description: Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
Study NCT04346472 — intervention group
Intervention type: OTHER
Intervention: Repeated Measurements of the relative regional cerebral blood volume
Description: Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
Study NCT04918212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fabulous Stent Graft System
Description: All patients received endovascular surgery using fabulous stent graft system
Study NCT03127657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cock's comb extract 0.01%
Description: Applied topically twice daily for 12 weeks
Study NCT03858491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
Study NCT04145778 — intervention group
Intervention type: OTHER
Intervention: 6-minute walk test
Description: The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
Study NCT01613521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI and 18F-FMISO PET
Description: DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Double-blind Maintenance
Description: Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Open-label
Description: Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
Study NCT03006913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person
Description: At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
Study NCT03006913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: By phone
Description: Patients in the phone arm will receive a scheduled call at their home.
Study NCT03006913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: By video
Description: Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
Study NCT03278990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value Affirmation and Future Selves Combination
Description: Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
Study NCT03278990 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control writing exercise
Description: In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
Study NCT03291210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal inspired oxygen fraction
Description: receives inspired oxygen fraction of 0.3
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide: Open-label
Description: Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
Study NCT04035408 — intervention group
Intervention type: OTHER
Intervention: Skin health assessment
Description: Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
Study NCT02247726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo (0.5mL injection)
Study NCT02247726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSV F vaccine (0.5mL injection)
Study NCT03291210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high inspired oxygen fraction
Description: receives inspired oxygen fraction of 0.8
Study NCT04049942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation group
Description: Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
Study NCT04049942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training group
Description: Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
Study NCT04014075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
Study NCT02622828 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Participant-identified community based activity
Description: The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
Study NCT02200848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Ibrutinib, Rituximab
Description: Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
Study NCT05568251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
Study NCT05568251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
Study NCT05568251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Participants will be administered Game of Dice Task concurrent with the tDCS session
Study NCT05568251 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Participants will be administered Game of Dice Task concurrent with the tDCS session
Study NCT02515409 — intervention group
Intervention type: DEVICE
Intervention: HHHFNC
Description: After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
Study NCT02515409 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: CPAP, as a first line treatment in OSAS.
Study NCT01254435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Recording of colonoscopic extubation
Study NCT01254435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Recording of colonoscopic extubation
Study NCT00666757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30-120 milligrams (mgs) orally daily for 12 weeks
Study NCT00666757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20-80 mgs orally daily for 12 weeks
Study NCT00666757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20-40 mgs orally daily for 12 weeks
Study NCT00666757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 20-50 mgs orally daily for 12 weeks
Study NCT00666757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50-200 mgs orally daily for 12 weeks
Study NCT00802399 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial Lacrimal Punctual Occlusion
Description: Cauterization of the edge of all lacrimal punctum was carried out in all patients
Study NCT01044602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory evaluations, sleep study
Description: Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
Study NCT01044602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management
Description: Standard of care.
Study NCT01044602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass surgery
Description: Surgical treatment.
Study NCT01609920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset enhanced MRL of axillary lymph nodes
Description: A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
Study NCT01957462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test V
Description: Coloplast Test product V is a newly developed 1-piece ostomy appliance
Study NCT01957462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test X
Description: Coloplast Test X is a newly developed 1-piece ostomy appliance
Study NCT01172951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: 75g anhydrous glucose powder mixed with 100mls water
Study NCT01172951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral lipid tolerance test
Description: 150ml drink composed of 2 commercially available high fat products
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: Participants will self-administer 56 mg of esketamine as intranasal spray.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: Participants will self-administer 84 mg of esketamine as intranasal spray.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer matching placebo as intranasal spray.
Study NCT01076413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skill based exercise
Description: 2 times per week for 12 weeks Pre gait and gait activities
Study NCT01076413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic conditioning
Description: 2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
Study NCT00527982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 600 mg by mouth daily for a total of 12 months.
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Aprepitant
Description: Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Ondansetron
Description: Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Dexamethasone
Description: Day 1: 12mg QD
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Olanzapine
Description: Day 1 to Day 5: 10mg QD
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral Antidepressant)
Description: Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram (Oral Antidepressant)
Description: Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
Study NCT03434041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
Study NCT02541071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film
Study NCT02541071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Study NCT02541071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT02541071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02780804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT02780804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02780804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02506335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cholate testing
Description: The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
Study NCT04091503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Modified Temozolomide
Description: Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard: Aprepitant
Description: Day 1: 125mg QD, Day 2 to Day3: 80mg QD
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard: Ondansetron
Description: Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
Study NCT03079219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard: Dexamethasone
Description: Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
Study NCT00421135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-201
Description: ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
Study NCT01785576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-Based CBT Intervention
Description: Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
Study NCT03123328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radical-7 Pulse CO-Oximeter and sensor
Description: Noninvasive device that measures hemoglobin.
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Substance misuse screening
Description: Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
Study NCT03506750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
Study NCT03162081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D
Description: Health related Quality of life